home / stock / evotf / evotf short
Short Information | Evotec Ag Ord (OTCMKTS:EVOTF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 4,963 |
Total Actual Volume | 18,628 |
Short Trends | |
---|---|
Cover Days | 3 |
Short Days | 15 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 248 |
Average Short Percentage | 76.38% |
Is there a EVOTF Short Squeeze or Breakout about to happen?
See the EVOTF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-24-2024 | $10.44 | $10.18 | $10.44 | $10.18 | 600 | 100 | 16.67% |
03-05-2024 | $13.93 | $13.83 | $13.93 | $13.83 | 200 | 100 | 50% |
02-05-2024 | $14.5 | $14.41 | $14.5 | $14.41 | 4,545 | 2,545 | 56% |
01-17-2024 | $16 | $16 | $16 | $16 | 250 | 100 | 40% |
01-04-2024 | $0 | $21.68 | $0 | $0 | 10,027 | 27 | 0.27% |
12-29-2023 | $23.97 | $24.61 | $24.61 | $23.97 | 300 | 300 | 100% |
10-23-2023 | $0 | $18 | $0 | $0 | 70 | 70 | 100% |
10-13-2023 | $18 | $18 | $18 | $18 | 100 | 100 | 100% |
10-02-2023 | $0 | $19.8 | $0 | $0 | 50 | 50 | 100% |
09-21-2023 | $20.73 | $19.8 | $20.73 | $19.8 | 300 | 100 | 33.33% |
09-01-2023 | $0 | $24.33 | $0 | $0 | 25 | 25 | 100% |
08-22-2023 | $0 | $24.33 | $0 | $0 | 20 | 20 | 100% |
08-17-2023 | $0 | $24.33 | $0 | $0 | 10 | 10 | 100% |
08-10-2023 | $0 | $24.33 | $0 | $0 | 20 | 20 | 100% |
07-27-2023 | $25.48 | $23.43 | $25.48 | $23.43 | 1,110 | 400 | 36.04% |
07-11-2023 | $23.37 | $23.37 | $23.37 | $23.37 | 105 | 100 | 95.24% |
06-26-2023 | $0 | $23.6 | $0 | $0 | 5 | 5 | 100% |
06-16-2023 | $23.6 | $23.6 | $23.6 | $23.6 | 690 | 690 | 100% |
06-12-2023 | $0 | $25.13 | $0 | $0 | 1 | 1 | 100% |
06-08-2023 | $25.13 | $25.13 | $25.13 | $25.13 | 200 | 200 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Evotec Ag Ord Company Name:
EVOTF Stock Symbol:
OTCMKTS Market:
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY BERLIN A...
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D&...
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was un...